Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.60 |
| ▸ | KDM4A | O75164 | 2/20 | 0.56 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | BCHE | P06276 | 4/20 | 0.53 |
| ▸ | ACHE | P22303 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HTR7 | P34969 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117737 | 0.87 | NSD2 (0.50) | SIGMAR1KDM4AKDM4CTMEM97NPC1 | |
| SCHEMBL4034244 | 0.81 | NSD2 (0.54) | SIGMAR1TMEM97NPC1RAB9ABCHE | |
| SCHEMBL19002498 | 0.77 | NSD2 (0.56) | SIGMAR1TMEM97NPC1RAB9AKMT2A | |
| SCHEMBL4072151 | 0.77 | NPC1 (0.85) | NPC1RAB9ABCHEACHEKMT2A | |
| SCHEMBL7039840 | 0.77 | SIGMAR1 (0.57) | SIGMAR1TMEM97NPC1KMT2AMEN1 | |
| SCHEMBL17372411 | 0.76 | SIGMAR1 (0.62) | SIGMAR1TMEM97KMT2AMEN1 | |
| SCHEMBL7398852 | 0.75 | KDM4A (0.74) | SIGMAR1KDM4AKDM4CTMEM97KMT2A | |
| SCHEMBL5118098 | 0.75 | NSD2 (0.63) | SIGMAR1TMEM97NPC1RAB9AKMT2A | |
| SCHEMBL17372581 | 0.75 | SIGMAR1 (1.00) | SIGMAR1TMEM97 | |
| SCHEMBL31612507 | 0.74 | TSHR (0.53) | SIGMAR1KDM4ATMEM97KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521744-B1 | ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS | FOURNIER LAB SA (FR) | 2009-04-01 | — | — | EP | disclosed |
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
| EP-1521744-A1 | ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS | LABORATOIRES FOURNIER S.A. (FR) | 2005-04-13 | — | — | EP | disclosed |
| WO-2003106428-A1 | NOVEL ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS THERAPEUTIC AGENTS | LABORATOIRES FOURNIER SA (FR) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | SIGMAR1 137/4885KDM4A 3324/4885KDM4C 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.